Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Thought leaders sits at the center of this dementia and brain health question.
Thought leaders in neurology and dementia care have proposed a comprehensive integrated treatment framework that fundamentally reimagines how Alzheimer’s disease is managed across the disease spectrum. Rather than treating Alzheimer’s as a single pathological process, this new framework recognizes that effective treatment requires simultaneously targeting multiple biological drivers of neurodegeneration—particularly amyloid and tau proteins—while using precise biomarker measurements to guide clinical decisions. The Alzheimer’s Association, working with leading researchers including UCSF’s Dr. Renaud La Joie, has developed and published the Treatment-Related Amyloid Clearance (TRAC) framework, a standardized approach that uses objective biomarker changes to measure how individual patients respond to anti-amyloid treatments, moving Alzheimer’s care closer to the individualized, evidence-based model that has transformed treatment of cancer and other complex diseases.
This shift toward integrated frameworks addresses a critical gap in current practice: historically, Alzheimer’s treatment decisions have relied heavily on clinical symptoms and general guidelines rather than personalized biomarker data. A patient presenting with early memory loss might receive the same treatment recommendation as another patient with identical symptoms, despite having completely different underlying pathology. The new integrated approach changes this by establishing clear, measurable standards for assessing treatment response and adjusting therapy accordingly, much like oncologists use tumor markers and imaging to guide cancer treatment decisions. For patients and families, this means treatment plans can now be tailored based on objective biological markers rather than educated guesses.
Table of Contents
- What Is the TRAC Framework and How Are Thought Leaders Reshaping Alzheimer’s Treatment?
- Multi-Pathway Approach: Combining Anti-Amyloid and Anti-Tau Therapies
- Biomarker-Guided Treatment Strategies and Personalized Care Planning
- Implementation in Clinical Practice: From Theory to Patient Care
- Challenges and Limitations of Integrated Treatment Frameworks
- Current Treatment Landscape and Recent Advances
- The Future of Coordinated Alzheimer’s Care
- Conclusion
What Is the TRAC Framework and How Are Thought Leaders Reshaping Alzheimer’s Treatment?
The Treatment-Related Amyloid Clearance (TRAC) framework, published in November 2025 in the Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, represents a major standardization effort in how researchers and clinicians characterize patient response to anti-amyloid medications. Led by Dr. Renaud La Joie at UCSF, a workgroup of scientists and clinicians established this framework to create consistency in measuring whether a patient’s brain amyloid levels are actually decreasing in response to treatment—a critical question that previously lacked standardized answers. The TRAC framework uses biomarker-based standards to objectively reflect changes in Alzheimer’s patients receiving anti-amyloid treatments, providing clinicians with clear metrics to determine if a particular drug is working for a particular patient.
Before this standardization, researchers and doctors across different institutions might measure amyloid clearance using different methods, making it difficult to compare treatment responses or predict which patients would benefit from continuing a medication. The TRAC framework solves this by establishing agreed-upon standards for what constitutes meaningful amyloid reduction. For example, if a patient on aducanumab or lecanemab shows amyloid reduction above the TRAC-defined threshold, clinicians can be confident that the biological target is being achieved. Conversely, if a patient shows minimal amyloid clearance despite medication compliance, the framework provides objective evidence that the treatment may not be working for that individual, potentially prompting a change in approach. This precision mirrors how oncologists use specific genetic mutations and tumor markers to predict which cancer drugs will be effective for individual patients.
Multi-Pathway Approach: Combining Anti-Amyloid and Anti-Tau Therapies
The integrated treatment framework moves beyond single-target therapies to address a fundamental reality of Alzheimer’s pathology: the disease involves not just amyloid-beta accumulation but also tau protein tangles, neuroinflammation, and neurodegeneration. Recent research, including a five-year clinical trial funded by the national Institutes of Health, demonstrates this multi-modal approach by combining anti-amyloid drugs with experimental anti-tau therapies, allowing researchers to test whether targeting both pathological pathways simultaneously produces better outcomes than treating amyloid alone. Early results suggest that patients whose brains show both amyloid and tau pathology may benefit most from coordinated treatment addressing both targets, rather than sequential or single-target approaches. However, this multi-pathway strategy also introduces complexity and potential limitations.
Combining multiple medications increases the risk of side effects and drug interactions, and it requires careful monitoring to ensure patient safety and tolerance. A patient enrolled in a multi-modal trial combining anti-amyloid and anti-tau drugs may experience more frequent medical appointments and laboratory testing than those on single treatments. Additionally, not all patients benefit equally from combination approaches—some may experience sufficient slowing of cognitive decline from anti-amyloid treatment alone, making the additional burden of a second medication medically unnecessary. The integrated framework addresses this challenge by using biomarkers to identify which patients truly have both pathologies and are therefore the best candidates for combination therapy, rather than prescribing multi-drug regimens to everyone.
Biomarker-Guided Treatment Strategies and Personalized Care Planning
At the core of the integrated framework is a shift toward biomarker-guided decision-making, where treatment recommendations are based on objective measurements of brain pathology rather than symptom severity alone. Thought leaders propose using digitally-facilitated algorithms that integrate biomarker data to guide risk stratification, early detection, timely diagnosis, and personalized preventative and therapeutic interventions. These algorithms can consider multiple data points—cerebrospinal fluid biomarkers, blood biomarkers, PET imaging, MRI findings, and genetic risk factors—to create a comprehensive risk profile for each patient and recommend tailored treatment pathways.
For instance, a 60-year-old patient with a family history of Alzheimer’s and positive amyloid biomarkers but normal cognitive function represents a very different treatment scenario than a 75-year-old with cognitive decline, negative amyloid biomarkers, and marked brain atrophy. The integrated framework allows clinicians to recognize these differences and recommend appropriate interventions: the cognitively normal but biomarker-positive patient might benefit from preventative anti-amyloid therapy, while the older patient with negative amyloid markers and prominent atrophy might be better served by cognitive rehabilitation and symptomatic treatment. This precision reduces overtreatment of patients unlikely to benefit and ensures that limited healthcare resources and patient effort are directed toward interventions with the highest likelihood of success.
Implementation in Clinical Practice: From Theory to Patient Care
Translating the integrated framework from published research into everyday clinical practice requires significant infrastructure changes and training. Healthcare systems must implement biomarker testing capabilities—including access to blood tests for phosphorylated tau and phosphorylated tau variants, cerebrospinal fluid analysis where appropriate, and imaging interpretation—to enable the stratification that the framework requires. Clinicians must learn to interpret biomarker results and integrate them with clinical assessment and patient preferences. Many community-based healthcare systems currently lack these capabilities, creating a practical barrier to rapid implementation.
The choice between biomarker-guided integrated treatment and traditional symptom-based approaches presents a genuine tradeoff. A healthcare system investing in comprehensive biomarker testing and digital decision-support algorithms incurs significant upfront costs and requires retraining staff. Conversely, continuing with traditional approaches avoids these costs but likely results in suboptimal treatment for many patients—some receiving drugs they won’t benefit from, others missing opportunities for preventative intervention. Early adopters and well-resourced institutions are already implementing aspects of the integrated framework, creating geographic disparities in access to personalized Alzheimer’s treatment that may worsen inequities in dementia care.
Challenges and Limitations of Integrated Treatment Frameworks
Despite the promise of integrated frameworks, significant challenges remain in widespread adoption and effectiveness. One critical limitation is that not all Alzheimer’s pathology can be fully captured by current biomarkers—neuroinflammation, vascular changes, and other contributing factors are less precisely measurable than amyloid and tau. This means even with the most comprehensive biomarker data, clinicians may miss important treatment targets.
Additionally, the long-term benefit of the integrated approach remains incompletely defined; while anti-amyloid treatments have demonstrated slowing of cognitive decline in early symptomatic disease, the degree of clinical benefit—whether slowing progression by months or years—continues to be refined. Another warning concerns equity and access: biomarker-guided integrated treatment requires expensive testing and sophisticated clinical infrastructure that may not be available in rural areas, economically disadvantaged communities, or countries with less developed healthcare systems. A patient in a major academic medical center might receive comprehensive biomarker testing and personalized treatment planning, while another patient with identical disease in a community clinic might receive only basic cognitive testing and generic medication recommendations. The integrated framework risks widening these disparities unless deliberate efforts are made to democratize access to biomarker testing and clinical decision support systems.
Current Treatment Landscape and Recent Advances
The landscape of Alzheimer’s treatment has changed markedly in recent years, with multiple anti-amyloid monoclonal antibodies now approved or in advanced trials, and anti-tau approaches moving from experimental to clinical testing. A comprehensive 2025 treatment review documented current strategies across the Alzheimer’s disease spectrum, from asymptomatic at-risk individuals through advanced dementia. The approval of lecanemab and the ongoing evaluation of donanemab represent proof that anti-amyloid strategies can translate to clinical benefit, validating the biological rationale underlying the integrated framework.
However, these treatments are not universally effective or appropriate. Lecanemab requires careful patient selection due to the risk of amyloid-related imaging abnormalities (ARIA), particularly in patients with the apolipoprotein E4 (APOE4) genetic variant. Some patients decline therapy due to the burden of regular infusions, cognitive side effects, or financial cost. The integrated framework helps identify which patients are the best candidates for anti-amyloid therapy and which might be better served by other interventions, including supportive care, cognitive rehabilitation, or management of concurrent conditions like hypertension and diabetes that contribute to cognitive decline.
The Future of Coordinated Alzheimer’s Care
As integrated treatment frameworks evolve and implementation expands, the future of Alzheimer’s care likely involves increasingly sophisticated combination therapies tailored to individual biomarker profiles, earlier intervention in asymptomatic at-risk stages, and integration of Alzheimer’s treatment with management of related conditions. Blood biomarkers are becoming increasingly accessible, potentially enabling routine screening and risk identification in primary care settings rather than requiring specialty referral.
Digital tools and artificial intelligence are expected to help clinicians navigate complex treatment algorithms and predict individual treatment responses. The trajectory suggests a continued convergence toward precision medicine in Alzheimer’s disease, where treatment decisions are based on objective biological data rather than generic protocols, much like the modern approach to cancer care. This represents both tremendous opportunity—for more effective, personalized treatment—and continued challenge, requiring sustained research, healthcare system investment, and commitment to equitable access so that the benefits of integrated frameworks reach all patients regardless of geography or economic resources.
Conclusion
Thought leaders have fundamentally reshaped Alzheimer’s treatment strategy through the development and promotion of integrated frameworks that address multiple pathological pathways, rely on objective biomarker guidance, and tailor therapy to individual patient characteristics. The TRAC framework, multi-modal drug trials, and biomarker-guided decision-making algorithms represent a major shift toward precision medicine in neurodegenerative disease, moving beyond one-size-fits-all treatment approaches toward individualized strategies based on each patient’s unique biological profile.
While implementation remains challenging and disparities in access persist, these frameworks represent significant progress in translating neuroscience discoveries into clinical practice. Patients and families navigating Alzheimer’s should discuss biomarker testing and integrated treatment approaches with their neurologist or dementia care specialist, particularly for early-stage disease where preventative and disease-modifying interventions are most likely to be beneficial. Healthcare systems should prioritize development of infrastructure and training to support biomarker-guided care, while researchers continue investigating how these integrated frameworks can be optimized, simplified, and made accessible to the broader population affected by Alzheimer’s disease.
You Might Also Like
- Scientific Advances Create Unprecedented Opportunities in Alzheimer’s Treatment
- Patients Report Positive Experiences With Long-Term Alzheimer’s Treatment
- Glial Cell Biology Research Advances Alzheimer’s Treatment Understanding
For more, see National Institute on Aging.
